Navigation Links
Beckman Coulter Acquires Rights to Hepatitis C Virus
Date:4/30/2008

Enables Development of Molecular Quantitative Viral Load Assay

ORANGE COUNTY, Calif., April 30 /PRNewswire-FirstCall/ -. Beckman Coulter, Inc. (NYSE: BEC) announced today that it has licensed certain rights to testing for the hepatitis C virus (HCV) from Siemens Healthcare Diagnostics. Under the agreement, Beckman Coulter can develop, manufacture and sell a quantitative viral load HCV blood test for use on the company's molecular diagnostic instrument, which is in development. As a result, Beckman Coulter expects to take a charge of $12 million in the second quarter of 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

HCV viral load testing is essential for managing patients affected by the hepatitis C virus and is used to monitor therapy for the duration of the infection. An estimated 180 million people are chronically infected with the hepatitis virus and an additional 3 to 4 million people are newly infected each year. A hepatitis C infection can cause acute hepatitis and chronic liver disease including cirrhosis and liver cancer. Two thirds of all liver transplants in developed countries are the result of these diseases(1).

Scott Garrett, chairman, president and CEO of Beckman Coulter, commented, "We are enthusiastic about the opportunity to meet our customers' growing needs for HCV testing. Our access to this intellectual property will expand the served market for our 'sample-to-result' molecular diagnostics system, expected to launch in 2010."

"We are pleased to collaborate with Beckman Coulter to broaden the availability of this important test," said Dave Okrongly, senior vice president, molecular diagnostics, Siemens Healthcare Diagnostics Division. "This agreement reaffirms Siemens' commitment to enable physicians worldwide to improve the health care they offer patients."

Garrett added, "Routine molecular testing is the fastest growing segment in clinical diagnostics and represents an important part of our growth strategy. The addition of HCV will enhance our infectious disease test menu while furthering our dedication to improving patient health and reducing the cost of care."

About Beckman Coulter

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company's 2007 annual revenue of $2.76 billion. For more information, visit http://www.beckmancoulter.com.

(1) World Health Organization (WHO) 2008. Web site accessed March 4, 2008: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.

Contacts: Allan Harris, Investor Relations

714.773.7620

adharris@beckman.com

Mary Luthy, Corporate Communications

714.773.7964

mluthy@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in ... pathogen detection. , PathSensors deploys the CANARY® test platform for the detection ...
(Date:4/27/2016)... ... , ... Global Stem Cells Group and the University of Santiago ... and development initiatives for potential stem cell protocol management for 2016 – 2020. ... began meeting to establish a working agenda and foster initiatives to promote stem cell ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice group. ... mechanical and electromechanical patent applications. He has an electrical engineering and computer engineering ...
Breaking Biology Technology:
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/15/2016)... 2016 --> --> ... Market Research "Digital Door Lock Systems Market - Global Industry ... the global digital door lock systems market in terms of ... is forecast to grow at a CAGR of 31.8% during ... medium enterprises (MSMEs) across the world and high industrial activity ...
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):